Purpose A comparison of thickness measurements of segmented spectral domain optical coherence tomography (OCT) derived topographic maps of patients with no or minimal diabetic retinopathy (DR) versus healthy controls. Methods Ninety‐nine patients, 44 with type 1 DM, and 36 with type 2 DM, with no or minimal DR underwent full ophthalmic examination, fundus photography and spectral domain OCT (3D OCT‐1000, Topcon). Following automated segmentation the mean thickness was calculated for 6 layers: 1/ Retinal Nerve Fibre Layer (RNFL), 2/ Ganglioncell layer (GCL) + Inner Plexiform Layer (IPL), 3/ Inner Nuclear Layer, 4/ Outer Plexiform Layer, 5/ Outer Nuclear Layer + Inner Segments (photoreceptor), 6/ Outer Segments (photoreceptor), in the ETDRS defined regions of the macula and compared to 76 age and sex matched healthy controls. Results The total retinal thickness in the diabetic patients was reduced compared to the healthy controls. In the diabetic patients both the mean RNFL and the mean OPL were significantly (p<0.05) thinner. Conclusion The decreased total retinal thickness in diabetic patients with no or minimal retinopathy may be due to a selective loss of thickness in several retinal layers and supports the concept of early DR as a neuro‐degenerative disease.
Purpose The purpose of this study was to investigate the macular retinal thickness, in relation to the axial length in amblyopic and normal eyes, using spectral domain OCT. Methods Included amblyopic and healthy children underwent a standard orthoptic examination and were scanned with spectral domain OCT (3D OCT‐1000, Topcon). The mean, nasal, temporal and foveal retinal thicknesses (RT) were used for analysis. We recorded the axial length using the IOL master (Zeiss). Nonparametric testing for paired data and correlations were performed using SPSS 14.0.2. Results Fifteen amblyopic patients (7 male and 8 females, mean age 8.2 ± 2) and 13 healthy children (7 males and 6 females, mean age 8.3 ± 1.5) were enrolled in this study. Compared to their fellow eyes the amblyopic eyes were 0.3 (0.6 – 0.1) mm shorter (p<.02) and had a 2.6 (0.6 – 4.5) micron thicker mean RT (p<.02) and a 4.2 (1.0 – 7.4) micron thicker temporal (p<.02) RT. No significant differences were found in the nasal and foveal minimal RT. In the normal controls none of the parameters differed significantly between both eyes (p>.05). The longer eyes were significantly correlated (r = 0.4, p<.04) with a thinner RT in this control group. However, after correcting for the axial length, the amblyopic eyes still had a significantly thicker mean and temporal RT (differences 3.4 (0.7 – 6.1) and 3.1 (0.6 – 5.5) micron, p<0.02). Conclusion Based on this study in 28 children, amblyopic eyes are slightly but significantly shorter and have thicker mean and temporal RT compared to their fellow eyes. The thicker RT in amblyopic eyes seems not to be explained by their shorter axial length.
Purpose: To evaluate OCT measured central retinal thickness (RT) in diabetes mellitus (DM) patients, with or without minimal diabetic retinopathy (DR). Methods: DM patients with or without minimal DR on biomicroscopy, were included and underwent a full ophthalmologic examination, (redfree) fundus photography and OCT scanning of the macula using StratusOCT (Zeiss). Mean RT measurements of the fovea (A1), pericentral ring (A2‐A5) and the peripheral ring (A6‐A9) in the patients were compared with RT measurements in normal, sex and age‐matched subjects. Results: One hundred DM patients were included in this study of which 50 type 1 and 50 type 2. Fundus photography showed either no abnormalities or only few microaneurysms in the posterior pole. The mean pericentral RT was significantly decreased in DM patients with and without minimal DR compared with the normal controls (n=100). The predicted value of the mean pericentral RT calculated with a regression model, based on the normal subjects, was not significantly different from the truly measured mean pericentral RT. Conclusions: In contrast with previous studies, we found that the pericentral RT in DM patients seems to be decreased compared to healthy subjects. This could be explained by the loss of intraretinal neurons in the earliest stage of DR. The use of a regression model suggests this neural tissue loss is not restricted to the pericentral region.
Purpose To demonstrate the flexibility and quality of a new SL‐FD‐OCT device, mounted on a slitlamp, in daily clinical practice. Methods Images were made in patients, with different types of macular pathology, and 30 patients with AMD, treated with ranibizumab, with a newly developed FD OCT scanning device integrated into a common slitlamp. Scans were made through a handheld lens (Volk 60 D), while simultaneously the (lesion in the) retina could be observed, with the slitlamp. A color fundus photograph of the observed area was made at the same time (Topcon camera DC1, resolution = 3.24 Mp). For comparison, line scans were made in the same patients with the Stratus‐OCT (Zeiss) and 3D‐volume scans with the 3D‐OCT‐1000(Topcon). Scans made at approximately the same location were subjectively compared with respect to quality of the images. Results With the new device scans, and photographs could be made without difficulty in all patients with a reasonably clear retinal image on slitlamp examination. The quality of the scans made with the new device is better than the Stratus‐OCT,and slighly less than the 3D‐OCT‐100. In 30 patients with exudative AMD, treated with ranibuzumab, conclusions regarding the presence of leakage based on SL‐FD‐OCT images were in concordance with the conclusions based on 3D volumes with the 3D‐OCT‐100(Topcon). Conclusion Quality of the scans made with the new device compare favourably with scans of the Stratus‐OCT (Zeiss), and are slightly less than scans made with the 3D‐OCT‐1000 (Topcon). The ease of use and the instanteneous availablity of results of OCT examination, during a regular clinical examination, could be very usefull in daily practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.